The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effects of body mass index on pretreatment characteristics, treatment choice, and response to treatment of intermediate- and high-grade prostate cancer.
Katherine Cox Ansley
No relevant relationships to disclose
Emma Holliday Ramahi
No relevant relationships to disclose
Gregory P. Swanson
No relevant relationships to disclose
Joseph W. Basler
Stock Ownership - Pfizer
Research Funding - Merck
Fei Du
No relevant relationships to disclose